Clockwise from L: John Maraganore, Andrew Lo and Mark McClellan
November 10, 2021 08:00 AM EST
Bioregnum
Cell/Gene Tx

The renowned drug hunter, the Wash­ing­ton in­sid­er, the MIT strate­gist: How did one low-pro­file biotech en­list a dream team of top biotech ad­vi­sors?

When you’re head­ing up a fledg­ling biotech out to make a name for your­self in the mid­dle of a wild in­dus­try boom, there’s one sure …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times